Regeneron Pharma gains as BofA upgrades rating
07/01/2026 18:14
** Shares of drugmaker Regeneron Pharmaceuticals REGN.O up 3.7% at $805.32 ** BofA Global Research upgrades rating to "buy" from "underperform"; raises PT to $860 from $627 ** New PT represents ~11% upside to stock's last close ** Brokerage views newer version of eye drug Eylea SD to be more positive in light of label updates ** "We see meaningful upside from Dupixent and late-stage pipeline assets entering 2026” — BofA ** Stock up 8.4% in 2025 (Reporting by Sanskriti Shekhar in Bengaluru ) ((Sanskriti.Shekhar@thomsonreuters.com))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)